The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
Open accessAbstract
Purpose: Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC. Methods: The impact of BMI (high BMI: ≥ 25 kg/m 2 v low BMI: < 25 kg/m 2) on overall survival (OS) and treatment outcome with targeted therapy was investigated in 1,975 patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and in an external validation cohort of 4,657 patients. Gene expression profiling focusing on fatty acid metabolism pathway, in The Cancer Genome Atlas data set, and immunohistochemistry staining for fatty acid synthase (FASN) were also investigated. Cox regression was undertaken to estimate the association of BMI with OS, adjusted for the IMDC prognostic factors. Results: In the IMDC cohort, median OS was 25.6 months (95% CI, 23.2 to 28.6) in patients with high BMI versus 17.1 months (95% CI, 15.5 to 18.5) in patients with low BMI (adjusted hazard ratio, 0.84; 95% CI, 0.73 to 0.95). In the validation cohort, high BMI was associated with improved OS (adjusted hazard ratio, 0.83; 95% CI, 0.74 to 0.93; medians: 23.4 months [95% CI, 21.9 to 25.3 months] v 14.5 months [95% CI, 13.8 to 15.9 months], respectively). In The Cancer Genome Atlas data set (n = 61), FASN gene expression inversely correlated with BMI (P = .034), and OS was longer in the low FASN expression group (medians: 36.8 v 15.0 months; P = .002). FASN immunohistochemistry positivity was more frequently detected in IMDC poor (48%) and intermediate (34%) risk groups than in the favorable risk group (17%; P-trend = .015). Conclusion: High BMI is a prognostic factor for improved survival and progression-free survival in patients with metastatic RCC treated with targeted therapy. Underlying biology suggests a role for the FASN pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“However, the relation between obesity, FASN, and outcome seems tumor specific.(7,28) A large TCGA investigation confirmed that FASN upregulation is associated with worse cancer-specific survival for ccRCC.”
Background
Cited by
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Self-citationWang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., Mirsoian, A., Minnar, C. M., Stoffel, K. M., Sturgill, I. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0221-5 · Cited by 865
“Surprisingly, recent clinical analyses demonstrate that obesity is associated with improved response and survival of cancer patients treated with targeted therapy and checkpoint blockade immunotherapy, although a mechanistic link was not elucidated 14,15 .”
The inflammatory pathogenesis of colorectal cancer
Schmitt, M., & Greten, F. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00534-x · Cited by 775
Epidemiology of Renal Cell Carcinoma: 2022 Update
Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A., Kassouf, W., Mitchell, T., Montironi, R., O'Brien, T., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.08.019 · Cited by 775
McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Self-citationCortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
Epidemiology and Risk Factors for Kidney Cancer
Scelo, G., & Larose, T. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.1905 · Cited by 305
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22323 · Cited by 87
Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial
Gelfond, J., Al-Bayati, O., Kabra, A., Iffrig, K., Kaushik, D., & Liss, M. A. (2018) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.04.011 · Cited by 22
Gillessen, S., Gobat, K., Cathomas, R., Fischer, N., Pereira Mestre, R., Hermanns, T., Rothschild, S. I., Mach, N., Mingrone, W., Ciriolo, M., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.03.001 · Cited by 4
Metadata
- Authors
- Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., Lee, J.-L., Rini, B. I., Srinivas, S., Bjarnason, G. A., Ernst, S., Wood, L. A., Vaishamayan, U. N., Rha, S.-Y., Agarwal, N., Yuasa, T., Pal, S. K., Bamias, A., Zabor, E. C., Skanderup, A. J., Furberg, H., Fay, A. P., de Velasco, G., Preston, M. A., Wilson, K. M., Cho, E., McDermott, D. F., Signoretti, S., Heng, D. Y. C., & Choueiri, T. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-10-20
- Volume
- 34
- Issue
- 30
- Pages
- 3655-3663
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2507163473
- Cited by
- 216
- References
- 3
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.